Flumatinib
Acute Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 4 / ApprovedActive
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 73/ 100
Competitive context
59 Active assets in the Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sawa Ito, MD | Phase 2/3 | BB |
Cyclophosphamide Sawa Ito, MD | Phase 4 | BB |
Cytosin-Arabinosid Janssen Research & Development, LLC | Phase 2/3 | BB |
Busulphan Sawa Ito, MD | Phase 4 | BB |
METHOTREXATE SWOG Cancer Research Network | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Flumatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →